公开(公告)号：US20140273081A1

公开(公告)日：2014-09-18

申请号：US14216339

申请日：2014-03-17

申请人： IRIS INTERNATIONAL, INC.

发明人： Jack Cremins ,  Carol Quon

IPC分类号： G01N1/30

CPC分类号： G01N15/1404 ,  G01N1/30 ,  G01N15/1434 ,  G01N15/1463 ,  G01N15/1468 ,  G01N15/147 ,  G01N15/1475 ,  G01N21/53 ,  G01N33/49 ,  G01N33/4915 ,  G01N33/5091 ,  G01N33/5094 ,  G01N33/80 ,  G01N2015/0065 ,  G01N2015/1037 ,  G01N2015/1411 ,  G01N2015/1413 ,  G01N2015/1452 ,  G01N2015/1486 ,  G01N2021/058

摘要： The present disclosure relates to a staining methodology employing a particle contrast agent composition capable of rapidly staining cells in a single step. The particle contrast agent composition can be comprised of a combination of one or more particle contrast agents, one or more permeabilizing agents, and one or more fixing agents. The particle contrast agent composition can include Crystal Violet, New Methylene Blue, Saponin, and Gluteraldehyde.

摘要翻译： 本公开内容涉及使用能够在一个步骤中快速染色细胞的颗粒造影剂组合物的染色方法。 颗粒造影剂组合物可以由一种或多种颗粒造影剂，一种或多种渗透剂和一种或多种固定剂的组合组成。 颗粒造影剂组合物可以包括结晶紫，新亚甲基蓝，皂苷和戊二醛。

公开(公告)号：US20140255972A1

公开(公告)日：2014-09-11

申请号：US14280612

申请日：2014-05-18

申请人： Ramot at Tel-Aviv University Ltd.

发明人： Reuven TIROSH ,  Fernando Patolsky ,  Hagit Peretz-Soroka

IPC分类号： G01N33/50

CPC分类号： G01N33/5091 ,  G01N33/5005 ,  G01N33/5023 ,  G01N33/5038 ,  G01N33/5094 ,  G01N33/84 ,  G06F19/12

摘要： A method of measuring a metabolic activity (MA) of a cell is provided. The method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:(i) non-volatile soluble metabolic products; (ii) non-volatile soluble metabolic products and volatile soluble metabolic products; and (iii) volatile soluble metabolic products; wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell. Also provided are clinical methods which make use of the assay.

摘要翻译： 提供了测量细胞的代谢活性（MA）的方法。 该方法包括在细胞的细胞外环境中独立测量，由于分泌以下因素而导致的时间依赖性酸化曲线：（i）非挥发性可溶性代谢产物; （ii）不挥发性可溶性代谢产物和挥发性可溶性代谢产物; 和（iii）挥发性可溶性代谢产物; 其中至少一个时间依赖性酸化曲线指示细胞的代谢活性。 还提供了利用该测定法的临床方法。

公开(公告)号：US20140234322A1

公开(公告)日：2014-08-21

申请号：US14268126

申请日：2014-05-02

申请人： Yuhchyau CHEN ,  J.H. David WU ,  Jane L. LIESVELD

发明人： Yuhchyau CHEN ,  J.H. David WU ,  Jane L. LIESVELD

IPC分类号： A61K31/4152 ,  A61K45/06 ,  A61K38/19 ,  C07K16/28 ,  A61K39/395

CPC分类号： A61K31/4152 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  A61K38/196 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/715 ,  C07K16/2866 ,  G01N33/5008 ,  G01N33/5094 ,  G01N2333/524

摘要： Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal. The chimeric thrombopoietin receptor comprises either the transmembrane domain of a human thrombopoietin receptor or both the extracellular and transmembrane domains of a human thrombopoietin receptor operably coupled to a cytoplasmic domain of a non-human thrombopoietin receptor.

摘要翻译： 公开了可用于筛选对血小板生成素受体有活性的血小板生成素模拟物，血小板生成素受体激动剂或血小板生成素受体拮抗剂的转基因非人哺乳动物。 转基因非人哺乳动物具有包含稳定整合的转基因构建体的基因组，其包含编码人源化血小板生成素受体的多核苷酸序列，其中所述转基因非人哺乳动物具有对应于匹配非血管生成素受体的生理血小板计数的基线血小板计数， 转基因非人哺乳动物。 嵌合血小板生成素受体包括人类血小板生成素受体的跨膜结构域或人血小板生成素受体的细胞外和跨膜结构域，其可操作地偶联至非人血小板生成素受体的细胞质结构域。

公开(公告)号：US20140220015A1

公开(公告)日：2014-08-07

申请号：US14253432

申请日：2014-04-15

申请人： Orban Biotech LLC

发明人： Tihamer Orban

IPC分类号： A61K39/395 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K38/1774 ,  A61K38/28 ,  A61K39/0008 ,  A61K45/06 ,  A61K2039/55566 ,  C07K14/4713 ,  C07K14/62 ,  C07K14/70521 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/5094

摘要： A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.

摘要翻译： 通过施用有效量的包含T细胞共刺激拮抗剂和部分免疫球蛋白分子的融合蛋白组合物和有效量的1型糖尿病来治疗，预防或延迟1型糖尿病进展的方法 糖尿病自身抗原 该方法包括例如施用细胞毒性T淋巴细胞相关抗原4（CTLA4）分子和1型糖尿病自身抗原。 也提供药物组合物。

公开(公告)号：US08663583B2

公开(公告)日：2014-03-04

申请号：US13337916

申请日：2011-12-27

申请人： Mark Kelley ,  Ron Bardell ,  Robert Janisch ,  Pam Wong ,  Eric Peltola

发明人： Mark Kelley ,  Ron Bardell ,  Robert Janisch ,  Pam Wong ,  Eric Peltola

IPC分类号： G01N21/00

CPC分类号： G01N33/5094 ,  B01L3/502738 ,  B01L2200/10 ,  B01L2300/0681 ,  B01L2300/0816 ,  B01L2300/0867 ,  B01L2300/0883 ,  B01L2400/0406 ,  B01L2400/049 ,  B01L2400/0655 ,  Y10T436/11

摘要： A disposable blood analysis cartridge may include a sample collection reservoir, an absorbance measurement channel, and an optical light scattering measurement channel. One or more valves may be disposed between the sample collection reservoir and the absorbance measurement channel and/or the optical light scattering measurement channel. A negative pressure may be applied to the cartridge to pull sample from the sample collection reservoir through the one or more valves and into the absorbance measurement channel and/or the optical light scattering measurement channel. Once the sample is pulled into the absorbance measurement channel and/or the optical light scattering measurement channel, the one or more valves may be closed. With the one or more valves closed, and in some cases, a pusher fluid may be provided to push the fluid sample to other regions of the disposable fluid blood analysis cartridge.

摘要翻译： 一次性血液分析盒可以包括样品收集容器，吸光度测量通道和光学散射测量通道。 一个或多个阀可以设置在样品收集容器和吸光度测量通道和/或光学光散射测量通道之间。 可以向盒施加负压，以将样品从样品收集容器中通过一个或多个阀拉入吸光度测量通道和/或光学光散射测量通道。 一旦将样品拉入吸光度测量通道和/或光学散射测量通道中，则可以关闭一个或多个阀。 在一个或多个阀关闭的情况下，并且在一些情况下，可以提供推动器流体以将流体样本推送到一次性液体血液分析盒的其它区域。

公开(公告)号：US20140057309A1

公开(公告)日：2014-02-27

申请号：US13672724

申请日：2012-11-09

申请人： Rauf Ahmetovich Gareyev

发明人： Rauf Ahmetovich Gareyev

IPC分类号： G01N33/50

CPC分类号： G01N33/5094 ,  G01N33/50

摘要： The method of the invention comprises preparing for analysis of a solution which contains substances, blood plasma, plus those substances which were present in whole blood within an adsorbed layer on blood cell surface. The method of the invention characterized in that substances which facilitate the transfer of the substances adsorbed on blood cell surface into the plasma are added to the whole blood sample. A sodium chloride hypertonic solution or a certain amount of a dry salt powder of sodium chloride is added.The method of the invention is intended for the analysis of all of the currently detectable endogenous substances and exogenous substances in blood but, in the first turn, for conducting pharmacological studies as well as for detecting tumor markers, immunomarkers, and doping control markers, which are transported in blood mostly on the blood cell surface.

摘要翻译： 本发明的方法包括准备分析含有物质，血浆，以及血细胞表面吸附层中全血中存在的那些物质的溶液。 本发明的方法的特征在于，将全部血液样品中添加有助于吸附在血细胞表面上的物质转移到血浆中的物质。 加入氯化钠高渗溶液或一定量的氯化钠干盐粉。 本发明的方法旨在分析血液中所有目前可检测的内源性物质和外源物质，但是在第一回合中，用于进行药物研究以及用于检测肿瘤标志物，免疫标记物和掺杂对照标记，其中 主要在血细胞表面上以血液运输。

公开(公告)号：US20140024019A1

公开(公告)日：2014-01-23

申请号：US14002879

申请日：2012-03-05

申请人： Jacobus Johannes Maria Van Dongen ,  José Alberto Orfao De Matos Correia E Vale

发明人： Jacobus Johannes Maria Van Dongen ,  José Alberto Orfao De Matos Correia E Vale

IPC分类号： G01N33/50

CPC分类号： G01N33/5094 ,  G01N33/5091 ,  G01N33/56972 ,  G01N2800/52

摘要： The invention relates to the field of medical diagnostics. Provided are methods and kits for determining the health status of a subject, for early detection of tissue damage, for early diagnosis and monitoring of a disease, and/or for evaluation of treatment effectiveness in a subject using circulating tissue macrophages (CTM) as a mirror of disrupted tissue homeostasis and disease.

摘要翻译： 本发明涉及医疗诊断领域。 提供了用于确定受试者的健康状况的方法和试剂盒，用于早期检测组织损伤，用于早期诊断和监测疾病，和/或用于使用循环组织巨噬细胞（CTM）作为评估受试者的治疗有效性 破坏组织体内平衡和疾病的镜子。

公开(公告)号：US20140017719A1

公开(公告)日：2014-01-16

申请号：US14033221

申请日：2013-09-20

申请人： HORIBA, Ltd.

发明人： Kazuhiro Miyamura

IPC分类号： G01N33/50

CPC分类号： G01N33/5094 ,  G01N1/38 ,  G01N15/12 ,  G01N33/49 ,  G01N2015/1006

摘要： Disclosed is a novel reagent for blood cell counting and a novel blood analysis method, which enable blood cells such as leukocytes to be counted with high accuracy by dissociating platelet aggregates in capillary blood collected from a living body. The reagent for blood cell counting is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, and is an aqueous solution containing a chloroquine salt.

摘要翻译： 公开了一种用于血细胞计数的新颖试剂和新颖的血液分析方法，其通过使从生物体收集的毛细血管血液中的血小板聚集体解离，能够高精度地计数白血球等细胞。 用于血细胞计数的试剂用于稀释从活体收集的毛细管血液以制备血液样品，以使用颗粒分析仪对收集的毛细管血液中的血细胞进行计数，并且是含有氯喹盐的水溶液。

公开(公告)号：US20130323125A1

公开(公告)日：2013-12-05

申请号：US13985383

申请日：2012-02-09

申请人： Steven Charles Deane

发明人： Steven Charles Deane

IPC分类号： G01N33/50

CPC分类号： G01N33/5094 ,  B01L3/5027 ,  B01L2200/0652 ,  B01L2200/10 ,  B01L2300/0645 ,  B01L2300/0816 ,  B01L2300/0867 ,  B01L2300/0883 ,  G01N15/1056 ,  G01N2001/383 ,  Y10T29/49117

摘要： A measurement chip (100) is disclosed for use with a microfluidic resistance network (20) comprising a microfluidic sample preparation stage (34, 38), a sample outlet (42) and a waste outlet (44) both in fluidic communication with said preparation stage. The measurement chip comprises a sample channel (104) for receiving a sample from said sample outlet (42), the sample channel comprising measurement means (120, 130) and having a first fluidic resistance; and a waste channel (114) for receiving a waste stream from said waste outlet (44) and having a second fluidic resistance.

摘要翻译： 公开了一种与微流体阻力网络（20）一起使用的测量芯片（100），该微流控阻抗网络（20）包括与所述制剂流体连通的微流体样品制备阶段（34,38），样品出口（42）和废物出口（44） 阶段。 测量芯片包括用于从所述样品出口（42）接收样品的样品通道（104），所述样品通道包括测量装置（120,130）并且具有第一流体阻力; 以及用于从所述废物出口（44）接收废物流并具有第二流体阻力的废物通道（114）。

公开(公告)号：US20130316375A1

公开(公告)日：2013-11-28

申请号：US13803581

申请日：2013-03-14

申请人： ORBAN BIOTECH LLC

发明人： Tihamer Orban

IPC分类号： G01N33/50

CPC分类号： G01N33/5094 ,  G01N33/564 ,  G01N33/56972 ,  G01N2800/042 ,  G01N2800/52

摘要： A new markers for insulin production decline in Type 1 diabetes has been found in the ratio the CD4 naïve (CD45RO-CD62L+) to central memory (CD45RO+CD62L+) and in the level of CD4 central memory T-cell subpopulations. A method of diagnosing autoimmunity and its progressiveness, more specifically diabetes, pre-diabetes, a susceptibility to diabetes mellitus, or the level of effectiveness of therapy/intervention modality for one or more of such conditions in a subject can be conducted by determining level of CD4 naïve (CD45RO-CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject; determining level of CD4 central memory (CD45RO+CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject, and quantitatively relating the levels of the CD4 naïve and central memory T-cells, wherein a low ratio of CD4 naïve T-cells to CD4 central memory T-cells and/or high CD4 central memory T-cell indicates autoimmunity, a susceptibility to autoimmunity, diabetes, pre-diabetes, a susceptibility to diabetes mellitus or ineffectiveness of a treatment for one or more of such conditions.

摘要翻译： CD4初始（CD45RO-CD62L +）与中央记忆（CD45RO + CD62L +）的比例和CD4中枢记忆T细胞亚群的水平之间，已经发现1型糖尿病胰岛素产生下降的新标志物。 诊断自身免疫及其进展的方法，更具体地说，糖尿病，糖尿病前期，对糖尿病的易感性，或者受试者中的一种或多种此类状况的治疗/干预模式的有效性水平可以通过确定 通过对从受试者提取的样品的免疫荧光分析，CD4初始（CD45RO-CD62L +）T细胞; 通过对从受试者提取的样品的免疫荧光分析来确定CD4中央记忆（CD45RO + CD62L +）T细胞的水平，并定量地将CD4初始和中央记忆T细胞的水平相关联，其中CD4初始T- 细胞对CD4中心记忆T细胞和/或高CD4中心记忆T细胞表示自身免疫，对自身免疫的敏感性，糖尿病，前期糖尿病，对糖尿病的易感性或治疗对于一种或多种这些病症的无效性。